Bloomberg News

Bristol-Myers' Daclatasvir, Asunaprevir Cured 77%: Study

April 19, 2012

Bristol-Myers Squibb Co. (BMY:US) said its experimental hepatitis C compounds, protease inhibitor asunaprevir combined with its NS5A inhibitor daclatasvir, cured 77 percent of difficult-to-treat patients 24 weeks after treatment ended, according to a mid-stage study.

Difficult-to-treat patients included those who didn’t respond to prior therapy and patients who were medically ineligible or intolerant to previous treatment, the company said in a statement today.

In a separate mid-stage study, Bristol-Myers’ experimental peginterferon lambda drug had a cure rate similar to peginterferon alfa with fewer side effects, the company said.

To contact the reporter on this story: Makiko Kitamura in London at

To contact the editor responsible for this story: Phil Serafino at

The Aging of Abercrombie & Fitch
blog comments powered by Disqus